Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/239074
Kind Code:
A1
Abstract:
A compound represented by formula (I), isomers or pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for treating diseases related to RIP-1 (receptor interacting protein) kinase.

Inventors:
WEI WEI (CN)
LI PENG (CN)
HE HAIYING (CN)
CHEN SHUHUI (CN)
Application Number:
PCT/CN2020/093280
Publication Date:
December 03, 2020
Filing Date:
May 29, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
MEDSHINE DISCOVERY INC (CN)
International Classes:
C07D403/12; A61P29/00; C07D413/12; C07D413/14; C07D417/04; C07D417/12; C07D513/04
Domestic Patent References:
WO2017136727A22017-08-10
WO1995014671A11995-06-01
WO2011071840A12011-06-16
Foreign References:
CN104418866A2015-03-18
CN201910471672A2019-05-31
CN201911089490A2019-11-08
CN202010432710A2020-05-20
Other References:
ZHU GUANGWEI, YE JIANXIN, HUANG YONGJIAN, ZHENG WEI, HUA JIN, YANG SHUGANG, ZHUANG JINFU, WANG JINZHOU: "Receptor-interacting protein-1 promotes the growth and invasion in gastric cancer", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 48, no. 6, 1 June 2016 (2016-06-01), pages 2387 - 2398, XP055883229, ISSN: 1019-6439, DOI: 10.3892/ijo.2016.3455
MENDES KEILA LOPES; LELIS DEBORAH DE FARIAS; SANTOS SÉRGIO HENRIQUE SOUSA: "Nuclear sirtuins and inflammatory signaling pathways", CYTOKINE AND GROWTH FACTOR REVIEWS, vol. 38, 1 December 2017 (2017-12-01), pages 98 - 105, XP085254003, ISSN: 1359-6101, DOI: 10.1016/j.cytogfr.2017.11.001
WEINLICH, R, NAT. REV. MOL. CELL. BIOL., vol. 18, 2017, pages 127
PASPARAKIS M. ET AL., NATURE, vol. 517, 2015, pages 311
BERGER, S.B., CELL DEATH DISCOVERY, vol. 2, 2016, pages el6056
LUKENS J. R. ET AL., NATURE, vol. 498, 2013, pages 224
See also references of EP 3978492A4
Attorney, Agent or Firm:
BEIJING ORIGINTELLIGENCE IP LAW FIRM (CN)
Download PDF: